Loading…
Hims & Hers Health, Inc. was cited for unlawfully selling unapproved and misbranded compounded semaglutide drugs through its website, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company made false or misleading claims stating its compounded semaglutide products contained "the same active ingredient as Ozempic and Wegovy" and were "clinically proven," implying equivalence to FDA-approved products when compounded drugs are not FDA-approved. These misbranding violations resulted in the prohibited introduction and delivery of drugs into interstate commerce under section 301(a) of the FDCA.